We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Avacta Group plc (AVCT) Ordinary Shares 10p

Sell:48.00p Buy:51.00p 0 Change: 3.00p (6.45%)
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:48.00p
Buy:51.00p
Change: 3.00p (6.45%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:48.00p
Buy:51.00p
Change: 3.00p (6.45%)
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Contact details

Address:
Unit 20, Ash Way
WETHERBY
LS23 7FA
United Kingdom
Telephone:
+44 (01904) 217070
Website:
https://avacta.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 30 September 2024 30/09/24
AGM 26 June 2024 26/06/24
Annual report 31 May 2024 31/05/24
Final results 30 April 2024 30/04/24
General meeting 18 March 2024 18/03/24

General stock information

EPIC:
AVCT
ISIN:
GB00BYYW9G87
Market cap:
£181.43 million
Shares in issue:
366.52 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Christina Coughlin
    Chief Executive Officer, Executive Director
  • Michelle Morrow
    Chief Scientific Officer
  • Simon Bennett
    Chief Business Officer - Therapeutics

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.